The Experimental Therapeutics service at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Medical Center is leading the development of new treatments for cancer. The Service gives our patients access to state of the art therapies through treatment on phase I clinical trials. These trials provide individuals diagnosed with cancer access to the some of the most promising new immunotherapy and molecularly targeted treatments. The Experimental Therapeutics Program brings together patients, physicians and scientists to advance cancer care and provide treatment options not previously available.
Our team of physician scientists use cutting edge laboratory techniques to understand each patient’s individual cancer and immune system to develop a personalized treatment plan. Our world-class clinical trials program allows us to match patients with the most promising new therapies based upon their individual cancer biology.
The clinical trials conducted in the Experimental Therapeutics Clinic are research studies that test new treatments to see how safe they are and how well they work. These experimental treatments are the most promising ones being developed for individuals with cancer and are only initially offered at a few cancer centers worldwide. The trials conducted in this clinic do not use a placebo. Patients who enroll on a clinical trial in the Experimental Therapeutics Clinic receive cutting edge cancer treatment from a treatment team focused on compassionate care.
To find a cancer-related clinical trial offered in the Experimental Therapeutics Service or elsewhere at the HICCC, go to Find a Clinical Trial.